文献速递抗栓抗凝管理药物不良反应与药物警戒

口服抗凝药与大出血风险的真实世界多中心前瞻性队列研究

Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study.
PubMed 文献 · Br J Clin Pharmacol · 2020-06-01

基于法国国家健康数据系统(SNIIRAM)在5个明确地理区域开展的人群前瞻性队列研究,纳入2013—2015年新使用口服抗凝药的47 469例成人,比较DOAC(按种类和剂量)与VKA的大出血风险。与VKA相比,高剂量和低剂量DOAC均与颅内出血风险降低相关(aHR 0.55,95%CI 0.37-0.82;aHR 0.54,95%CI 0.26-1.12),其他大出血事件风险亦降低(aHR 0.41,95%CI 0.29-0.58;aHR 0.41,95%CI 0.22-0.79),但大胃肠道出血风险与VKA无显著差异。

要点

  • 与VKA相比,高剂量和低剂量DOAC均与颅内出血风险降低相关。
  • 与VKA相比,DOAC与其他大出血事件风险降低相关。
  • DOAC与VKA在大胃肠道出血风险上无显著差异。

核心结论

  • 使用DOAC在颅内出血方面具有明确获益。
  • 研究为大胃肠道出血和其他大出血事件提供了新见解。

研究设计与样本

  • 研究为基于法国国家健康数据系统(SNIIRAM)的人群前瞻性队列研究。
  • 纳入5个明确地理区域内2013—2015年新使用口服抗凝药的47 469例成人:VKA 20 205例、利伐沙班19 579例、达比加群4 225例、阿哌沙班3 460例。
  • 从上述区域所有急诊科收集因出血就诊成人的临床数据并进行医学验证,数据库按共同关键变量链接。
  • 主要结局为大出血:颅内出血、大胃肠道出血和其他大出血事件;风险比来自校正Cox比例风险模型。
  • 敏感性分析采用倾向评分加权,并按适应证(心房颤动或静脉血栓栓塞症)分别分析。

主要发现

  • 与VKA相比,高剂量DOAC与颅内出血风险降低相关(aHR 0.55,95%CI 0.37-0.82)。
  • 与VKA相比,低剂量DOAC与颅内出血风险降低相关(aHR 0.54,95%CI 0.26-1.12)。
  • 与VKA相比,高剂量DOAC与其他大出血事件风险降低相关(aHR 0.41,95%CI 0.29-0.58)。
  • 与VKA相比,低剂量DOAC与其他大出血事件风险降低相关(aHR 0.41,95%CI 0.22-0.79)。
  • 无论DOAC剂量如何,大胃肠道出血风险与VKA均无显著差异。

临床怎么用

  • 在真实临床实践中,选择DOAC而非VKA可能降低颅内出血和其他大出血事件风险。
  • 对需关注大胃肠道出血风险的患者,DOAC与VKA的选择应结合个体情况综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The objective was to compare major bleeding risk of direct oral anticoagulants (DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication, using real-world data. METHODS: A population-based prospective cohort study, using the French national health data system (SNIIRAM), identified 47 469 adults living within 5 well-defined geographical areas, who were new users of oral anticoagulants in the period 2013-2015: 20 205 VKA users, 19 579 rivaroxaban users, 4225 dabigatran users and 3460 apixaban users. From all emergency departments within these areas, clinical data for all adults referred for bleeding was collected and medically validated. The databases were linked for common key variables. The main outcome measure was major bleeding: intracranial haemorrhage, major gastrointestinal bleeding and other major bleeding events. Hazard ratios were derived from adjusted Cox proportional hazard models. We used propensity score weighting as a sensitivity analysis, with separate analyses according to indications (atrial fibrillation or venous thromboembolism). RESULTS: Compared to VKAs, high and low-dose DOACs were associated with a reduced risk of intracranial haemorrhage (adjusted hazard ratio 0.55, 95% confidence interval 0.37-0.82 and 0.54, 0.26-1.12 respectively), and a reduced risk of other major bleeding events (0.41, 0.29-0.58 and 0.41, 0.22-0.79 respectively), irrespective of duration and indication. Neither DOAC dose evidenced any significant difference from VKAs in terms of risk of major gastrointestinal bleeding. CONCLUSION: There is a clear benefit of using DOACs with regard to intracranial haemorrhage. The study provides new insight into major gastrointestinal and other major bleeding events.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Bouget J, Balusson F, Maignan M, et al. Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study. Br J Clin Pharmacol. 2020. PMID: 32415705. doi:10.1111/bcp.14362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。